Melkersson-Rosenthal syndrome with underlying sarcoidosis in a middle aged female patient
DOI:
https://doi.org/10.66344/jpad.v34i4(Suppl).2972Abstract
Melkersson-Rosenthal syndrome (MRS) is a rare entity. It is often described as a triad of facial swelling, facial nerve palsy and a plicated tongue, but may be diagnosed when two of the above symptoms are seen. It is characterized by a granulomatous inflammation on histological examination and hence disorders such as Sarcoidosis, Inflammatory Bowel Disease and Tuberbulosis are implicated in the etiology. Response to treatment can be disappointing, with most patients having recurrent episodes over a chronic course. Here we present a case of a 45 year old woman who presented with gradual orofacial edema for the last 7 months which she first noted after her Covid vaccination. It was followed by the appearance of left sided facial nerve palsy. Upon investigation, we found radiological evidence of pulmonary sarcoidosis and raised serum Angiotensin Converting Enzyme levels. A biopsy from her lip showed granulomatous inflammation. We treated her with high dose systemic steroids, Mycophenolate Mofetil and Methotrexate. The combination of orofacial edema, facial nerve palsy and a fissured tongue (together called the Melkersson–Rosenthal syndrome) remains a rare presentation with less than 40 cases having been reported in literature. Investigating the patient may uncover an underlying diagnosis of a systemic granulomatous disorder such as Sarcoidosis, or other etiologies including infections and autoimmune conditions. There are no established guidelines towards treatment and the choice of therapy depends upon an individual case-by-case approach and the physician’s discretion.
References
1. Taşlıdere B, Mehmetaj L, Özcan AB, Gülen B, Taşlıdere N. Melkersson-Rosenthal syndrome induced by COVID-19. Am J Emerg Med. 2021;41:62.e5-262.e7.
2. Haaramo A, Kolho KL, Pitkäranta A, Kanerva M. A 30-year follow-up study of patients with Melkersson–Rosenthal syndrome shows an association to inflammatory bowel disease. Ann Med. 2019;51(2):149-55.
3. Casper J, Mohammad-Khani S, Schmidt JJ, Kielstein JT, Lenarz T, Haller H, Wagner AD. Melkersson–Rosenthal syndrome in the context of sarcoidosis: a case report. J Med Case Rep. 2021;15(1):1-6.
4. Gavioli CF, Florezi GP, Lourenço SV, Nico MM. Clinical profile of Melkersson-Rosenthal syndrome/ orofacial granulomatosis: A review of 51 patients. J Cut Med Surg. 2021;25(4):390-6.
5. Gavioli CF, Nico MM, Florezi GP, Lourenço SV. The histopathological spectrum of Melkersson‐Rosenthal syndrome: analysis of 47 cases. J Cut Pathol. 2020;47(11):1010-7.
6. Dhawan SR, Saini AG, Singhi PD. Management strategies of Melkersson-Rosenthal syndrome: a review. Int J Gen Med. 2020:61-5.
7. Mansour M, Mahmoud MB, Zaouali J, Mrissa R. Melkersson-Rosenthal syndrome: About a Tunisian family and review of the literature. Clin Neurol Neurosurg. 2019;185:105457.
8. Okudo J, Oluyide Y. Melkersson-Rosenthal syndrome with orofacial swelling and recurrent lower motor neuron facial nerve palsy: a case report and review of the literature. Case Rep Otolaryngol. 2015;2015:214946.
9. Savasta S, Rossi A, Foiadelli T, Licari A, Elena Perini AM, Farello G, Verrotti A, Marseglia GL. Melkersson–Rosenthal syndrome in childhood: report of three paediatric cases and a review of the literature. Int J Environ Res Pub Health. 2019;16(7):1289.
10. Snoussi M, Frikha F, Mnif H, Chebbi D, Marzouk S, Boudawara T, Bahloul Z. Granulomatous gingival manifestation in Melkersson Rosenthal syndrome: a case report. The Pan African Med J. 2023;44:72.
11. Taslidere B, Mehmetaj L, Özcan AB, Gülen B, Taslidere N. Melkersson-Rosenthal Syndrome Induced by COVID-19. Am J Emerg Med. 2021:262-e5.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Amna Saeed, Anam Tanveer, Hafsa Saeed, Wajieha Saeed, Ijaz Hussain

This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.






